Employees: 4,697
Size Nanjing Pharmaceutical (600713.SS) is a China Health Care company (Medical Distributors) with a market value of $999M, the 2166th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.12 on 18 Nov 2026.
Performance Over six months the shares fell 2.1%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +5.0%); the operating margin is 2.5% (peer median 1.5%).
Valuation It trades at 0.3× enterprise value to sales against a peer median of 0.7× (6th cheapest of 21).
Capital Return on invested capital runs 0.8 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥55.5B | CN¥54.9B | CN¥53.6B | CN¥53.5B | CN¥50.2B |
| Revenue growth | — | +2% | 0% | +7% | — |
| Gross profit | CN¥3.51B | CN¥3.06B | CN¥3.04B | CN¥2.98B | CN¥2.93B |
| EBITDA | n/a | CN¥1.60B | CN¥1.78B | CN¥1.77B | CN¥1.64B |
| Net income | CN¥638M | CN¥625M | CN¥571M | CN¥578M | CN¥596M |
| Free cash flow | -CN¥1.70B | -CN¥153M | CN¥1.59B | CN¥1.75B | -CN¥835M |
| Capital expenditure | CN¥215M | CN¥251M | CN¥545M | CN¥158M | CN¥155M |
| Total debt | CN¥12.1B | CN¥9.04B | CN¥12.6B | CN¥11.6B | CN¥15.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600713.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.4% | -2.0% | 7th highest of 21 |
| 6-month return | -2.1% | -3.7% | 10th highest of 21 |
| Distance from 52-week high | -23.0% | -20.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +3.0% | +5.0% | 9th lowest of 21 |
| Operating margin | 2.5% | 1.5% | 9th highest of 21 |
| EV / Sales | 0.3× | 0.7× | 6th cheapest of 21 |
| ROIC minus cost of capital | +0.8 pp | +0.0 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 1.9× | 17.0% | +12.4% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 0.2× | -14.5% | +7.6% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | 0.5× | n/a | n/a |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 0.1× | -4.6% | +5.1% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 0.1× | -10.4% | +3.2% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | 288.8× | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | 0.6× | 58.3% | -7.8% |